Left Heart Failure clinical trials

Explore recruiting left heart failure clinical trials.

Recruiting left heart failure studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Left Heart Failure trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

(14308) Randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the hemodynamic effects of Riociguat (BAY 63-2521) as well as safety and kinetics in patients with pulmonary hypertension associated with left ventricular systolic dysfunction.

Italy, Czechia, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes – DISCO Study

France

Therapeutic use (Phase IV) EU CTIS Study details

LEVOMEMS: Comparison of the Hemodynamic Profile of Dobutamine and Levosimendan in the Current Therapeutic Context

Spain

Phase III and phase IV (Integrated) EU CTIS Study details

Phase 2, Multicenter, Randomized, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction (≤ 45%) After Myocardial Infarction (HF-REVERT)

Poland, Spain, Czechia, Greece, Netherlands, Germany +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I-IIa Trial on the Safety and Preliminary Effectiveness of Intramyocardial Injection of Cardiac Atrial Stem Cells for the Treatment of Advanced Ischemic Heart Failure in Subjects with Ischemic Left Ventricular Dysfunction and Chronic Myocardial Infarction.

Belgium

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Left Heart Failure trials by city

Left Heart Failure in Toronto Left Heart Failure in Vancouver Left Heart Failure in Montreal Left Heart Failure in Calgary Left Heart Failure in Edmonton Left Heart Failure in Ottawa Left Heart Failure in Winnipeg Left Heart Failure in Quebec City Left Heart Failure in Hamilton Left Heart Failure in Kitchener Left Heart Failure in London Left Heart Failure in Halifax Left Heart Failure in New York Left Heart Failure in Los Angeles Left Heart Failure in Chicago Left Heart Failure in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease